Stock 6955 SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Shandong Boan Biotechnology Co., Ltd.

Equities

6955

CNE100005RV4

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-05-10 am EDT 		5-day change 1st Jan Change
10.2 HKD +1.39% Intraday chart for Shandong Boan Biotechnology Co., Ltd. -1.16% -34.19%
Apr. 12 Shandong Boan Biotechnology Co., Ltd. Enters into Loan Facility with China Jingu International Trust Co., Ltd CI
Apr. 08 Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Boan Biotechnology Co., Ltd. Enters into Loan Facility with China Jingu International Trust Co., Ltd
CI
Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection
MT
Shandong Boan Biotechnology Co., Ltd. Completes Phase 3 Clinical Trial in China for Aflibercept Intravitreous Injection and Plans to Submit Biologics License Application
CI
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
MT
Shandong Boan Biotechnology Trims Attributable Loss in 2023
MT
Shandong Boan Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shandong Boan Biotech Completes Phase 3 Trial for Type 2 Diabetes Injection; Shares Surge 10%
MT
Shandong Boan Biotechnology Co., Ltd. Announces Phase 3 Clinical Trial Completed in China for Dulaglutide Injection
CI
Shandong Boan Biotechnology Authorizes CDMO Service Provider to Use Stable Cell Line Development Platform
MT
Shandong Boan Biotechnology Co., Ltd. Enters into Agreement with the Zencore Biologics Co., Ltd
CI
Boan Biotechnology, Joincare Sign Exclusive License Deal for Respiratory Disease Treatment
MT
Shandong Boan Biotechnology Co., Ltd. Announces Orphan Drug Designations for Treatment of Gastric Cancer by FDA
CI
Boan Biotechnology Secures Brazilian GMP Certification For Cancer Drug
MT
Shandong Boan Biotechnology Co., Ltd. Obtains GMP Certification for Boyuno®? from the Brazilian Agencia Nacional De Vigilancia Sanitaria
CI
Boan Biotech Completes Enrollment for International Multicenter Comparative Clinical (Phase 3) Study of Its Denosumab
CI
Shandong Boan Enrolls Participants for Denosumab Injection Trials in EU, US and Japan
MT
Certain H Shares of Shandong Boan Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-DEC-2023.
CI
Shandong Boan Biotechnology Gets Orphan Drug Designations for Pancreatic Cancer Treatment
MT
Shandong Boan Biotechnology Sells Equipment for Leaseback
MT
Shandong Boan Biotechnology Co., Ltd. Announces Resignation of Chen Jie as Non-Executive Director
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6955 Stock
  4. News Shandong Boan Biotechnology Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW